NEW YORK, August 4, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Laboratory Corporation of America Holdings
(NYSE: LH), DexCom Inc. (NASDAQ: DXCM), Bruker Corporation (NASDAQ:
BRKR), WuXi PharmaTech (NYSE: WX), and Great Basin Scientific Inc.
(NASDAQ: GBSN). Free research report on Laboratory Corp. of America
Holdings can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=LH On
Monday, August 03, 2015, the NASDAQ
Composite ended at 5,115.38, down 0.25%, the Dow Jones Industrial
Average lost 0.52%, to finish the day at 17,598.20, and the S&P
500 closed at 2,098.04, down 0.28%. The losses were broad based as
seven out of nine sectors ended the session in negative. Register
for your complimentary reports at the links given below.
Laboratory Corp. of America Holdings' stock edged 0.05% higher
to close the day at $127.35. The
stock recorded a trading volume of 1.35 million shares, above its
three months average volume of 1.14 million shares. Over the last
one month and over the past three months, Laboratory Corp. of
America Holdings' shares have gained 5.47% and 6.85%, respectively.
Furthermore, the stock has surged 18.03% since the start of this
year. The company's shares are trading 5.32% above their 50-day
moving average and 9.77% above their 200-day moving average.
Additionally, Laboratory Corp. of America Holdings traded at a PE
ratio of 27.51 and has a Relative Strength Index (RSI) of 66.17.
Sign up and read the free notes on LH at:
https://www.EquityResearchInstitute.com/reports?keyword=LH
On Monday, shares in DexCom Inc. recorded a trading volume of
0.44 million shares, lower than their three months average volume
of 0.84 million shares. The stock ended the day 0.14% lower at
$84.53. DexCom Inc.'s stock has
surged 6.51% in the last one month, 23.96% in the previous three
months and 53.55% on YTD basis. The company is trading above its
50-day and 200-day moving averages by 8.94% and 33.65%,
respectively. Furthermore, shares of DexCom Inc. have an RSI of
63.72. The complimentary notes on DXCM can be downloaded in PDF
format at:
https://www.EquityResearchInstitute.com/reports?keyword=DXCM
Bruker Corp.'s stock gained 1.95%, to close Monday's session at
$21.46. The stock recorded a trading
volume of 1.03 million shares, above its three months average
volume of 0.81 million shares. Over the last one month and the
previous three months, Bruker Corp.'s shares have advanced 5.35%
and 10.16%, respectively. Additionally, the stock has gained 9.38%
since the start of this year. The company is trading 4.34% and
9.30% above its 50-day and 200-day moving averages, respectively.
Furthermore, Bruker Corp.'s stock traded at a PE ratio of 67.06 and
has an RSI of 59.37. Register for free on Equity Research Institute
and access the latest research on BRKR at:
https://www.EquityResearchInstitute.com/reports?keyword=BRKR
WuXi PharmaTech's stock finished Monday's session 0.55% higher
at $41.73. A total of 0.29 million
shares were traded, which was below its three months average volume
of 0.65 million shares. Over the last one month and the previous
three months, WuXi PharmaTech's shares have fallen by 0.22% and
7.33%, respectively. However, the stock has surged 23.94% since the
beginning of 2015. The company's shares are trading above their
200-day moving average by 6.55%. WuXi PharmaTech's stock traded at
a PE ratio of 26.58 and has an RSI of 47.85. The complete research
on WX is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=WX
On Monday, shares in Great Basin Scientific Inc. ended the
session 1.43% lower at $2.75. The
stock reported a trading volume of 0.05 million shares, below its
three months average volume of 0.51 million shares. Great Basin
Scientific Inc.'s shares have declined 6.14% in the last one month
and 31.48% in the previous three months. However, the stock has
gained 11.79% on YTD basis. The company is trading 10.88% below its
50-day moving average and 13.91% below its 200-day moving average.
Moreover, shares of Great Basin Scientific Inc. have an RSI of
44.65. Free in-depth research on GBSN is available at:
https://www.EquityResearchInstitute.com/reports?keyword=GBSN
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com